Blocking complement factor B halts pancreatic cancer growth

Researchers have identified a promising new target in the treatment of pancreatic cancer. A new study in The American Journal of Pathology , published by Elsevier, demonstrates that blocking complement factor B (CFB), a pivotal enzyme in the alternative complement pathway, halts cancer growth and alters the tumor microenvironment.

The greatest tumor suppression was observed when CFB inhibition was combined with chemotherapy and immunotherapy. Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult cancers to treat, in large part because of its highly immunosuppressive nature. Effective therapies are limited, and the five-year survival rate is below 15%.

The researchers of this study first examined the clinical significance of CFB in human PDAC tissues and found that high levels of the enzyme in the connective tissue surrounding the tumor were associated with poorer patient survival rates and more frequent hematogenous recurrence.

They then investigated the effects of the selective CFB inhibitor iptacopan in pancreatic cancer cells and found that CFB blockade reduced cancer cell proliferation and promoted cellular senescence, accompanied by increased expression of p21, a protein that signals cancer cells to stop growing.

Iptacopan is an already approved first-in-class oral CFB inhibitor that has shown clinical efficacy and safety in certain rare complement-mediated diseases. In our previous research, we identified that CFB is upregulated during PDAC development. This led us to test the use of iptacopan in a mouse model of PDAC." Shigetsugu Takano, MD, PhD, lead investigator, Department of General Surgery, Chiba University, Graduate School of Medicine, Japan Lead author Daren Zhou, MD, PhD, Department of General Surgery, Chiba University, Graduate School of Medicine, Japan, adds, "We demonstrated that iptacopan significantly suppressed tumor growth.

Importantly, CFB blockade also altered the tumor immune microenvironment. We saw a decrease in regulatory T cells together with increased CD8+ T-cell infiltration, suggesting that CFB blockade was doing more than directly affecting tumor cells; it was also reshaping the immune context of the tumor.

This finding led us to explore combination therapy with immune checkpoint blockades, where we observed additional antitumor activity." Because pancreatic cancer creates an exceptionally immunosuppressive environment, targeting the tumor cells directly via immunotherapy has had limited success.

This study shows that CFB may be one of the mechanisms helping to maintain that defensive environment. CFB inhibition targets both the cancer cells and their surroundings. Dr.

Takano concludes, "Our findings support iptacopan's potential as a combination therapy with chemotherapy and immunotherapy, although further preclinical and clinical studies are needed. We hope these findings will contribute to developing new, more effective treatments for pancreatic cancer." Source: Journal reference: Zhou, D., et al . (2026).

Complement factor B blockade by IPTACOPAN drives antitumor complement-based immunomodulation in pancreatic cancer microenvironment. The American Journal of Pathology . DOI: 10.1016/j.ajpath.2026.08.005. https://ajp.amjpathol.org/article/S0002-9440(26)00257-9/fulltext Suggested Reading Terms While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses.

Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information. Read the full Terms & Conditions .